The inhibition of the NLRP1 inflammasome by Tim-4 in liver macrophages through the LKB3/AMPKα pathway serves as an intervention strategy for NAFLD progression. Here, TIMD4 is linked to metabolic dysfunction-associated steatotic liver disease.